Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years.
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 11 Sep 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2009-013710-27).
- 01 May 2011 Results published in Clinical and Vaccine Immunology.
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.